Send to

Choose Destination
See comment in PubMed Commons below
J Hosp Infect. 2012 Dec;82(4):281-5. doi: 10.1016/j.jhin.2012.08.007. Epub 2012 Oct 22.

Impact of Port-A-Cath device management in cancer patients with candidaemia.

Author information

Division of Haematology and Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.


This study investigated the impact of management of a totally implantable central venous access port device, Port-A-Cath (Smith Medical, St. Paul, MN, USA), on the outcome of 98 cancer patients with candidaemia. Port-A-Cath retention was found to be significantly associated with poorer outcome, independent of other significant adverse factors [breakthrough candidaemia, Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥ 21, and worse Eastern Cooperative Oncology Group (ECOG) performance score (3-4)]. However, retention of Port-A-Cath devices could be considered in patients who do not have definite catheter-related candidaemia, are not using total parenteral nutrition, do not have poor ECOG performance scores or APACHE II scores, and do not have septic shock.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center